We are live on
!
Find out more
BCM
Boone Capital Management Portfolio holdings
AUM
$326M
1-Year Est. Return
86.31%
This Fund
S&P 500
This Quarter
Est. Return
+59.26%
1 Year Est. Return
+86.31%
3 Year Est. Return
+255.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$305M
AUM Growth
+$71.8M
(+31%)
Cap. Flow
+$13.8M
Cap. Flow
% of AUM
4.53%
Top 10 Holdings %
Top 10 Hldgs %
83.1%
Holding
19
New
8
Increased
1
Reduced
4
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BridgeBio Pharma
BBIO
|
+$22.4M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$20.4M |
| 3 |
Cigna
CI
|
+$14M |
| 4 |
Cogent Biosciences
COGT
|
+$11.2M |
| 5 |
RAPT
RAPT Therapeutics
RAPT
|
+$10.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Avantor
AVTR
|
+$22.8M |
| 2 |
Unum
UNM
|
+$22.8M |
| 3 |
Pennant Group
PNTG
|
+$19.4M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$6.8M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$6.72M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Medtronic
MDT
$108B
| $40.8M | 13.39% |
428,789
| – | – |
|
|
2
Mirum Pharmaceuticals
MIRM
$6.55B
| $39.3M | 12.88% |
535,732
-105,716
| -16% | -$6.72M |
|
|
3
Ionis Pharmaceuticals
IONS
$8.57B
| $27.3M | 8.96% |
+417,833
| New | +$20.4M |
|
|
4
Cigna
CI
$75.1B
| $23.9M | 7.84% |
82,972
+47,372
| +133% | +$14M |
|
|
5
BridgeBio Pharma
BBIO
$15.6B
| $23.9M | 7.84% |
+460,282
| New | +$22.4M |
|
6
Neurocrine Biosciences
NBIX
$16.9B
| $23.4M | 7.66% |
166,414
-13,924
| -8% | -$1.89M |
|
|
RAPT
7
DELISTED
RAPT Therapeutics
RAPT
| $20.2M | 6.62% |
+782,461
| New | +$10.2M |
|
8
UnitedHealth
UNH
$382B
| $20.1M | 6.58% |
58,112
| – | – |
|
|
9
BioMarin Pharmaceuticals
BMRN
$11.5B
| $17.8M | 5.83% |
328,546
-118,903
| -27% | -$6.8M |
|
10
Icon
ICLR
$12.6B
| $16.8M | 5.5% |
95,832
| – | – |
|
|
11
Cogent Biosciences
COGT
$6.72B
| $13.6M | 4.45% |
+945,042
| New | +$11.2M |
|
12
Kodiak Sciences
KOD
$2.6B
| $11.7M | 3.84% |
+715,877
| New | +$6.17M |
|
13
LivaNova
LIVN
$4.4B
| $8.8M | 2.88% |
+167,932
| New | +$8.45M |
|
14
uniQure
QURE
$3.03B
| $8.6M | 2.82% |
+147,317
| New | +$2.67M |
|
15
ClearPoint Neuro
CLPT
$441M
| $6.19M | 2.03% |
+283,912
| New | +$3.34M |
|
16
Abeona Therapeutics
ABEO
$358M
| $2.66M | 0.87% |
502,854
-751,804
| -60% | -$4.77M |
|
|
17
Avantor
AVTR
$9.2B
| – | – |
-1,694,482
| Closed | -$22.8M |
|
|
18
Pennant Group
PNTG
$1.4B
| – | – |
-649,022
| Closed | -$19.4M |
|
|
19
Unum
UNM
$13.7B
| – | – |
-281,790
| Closed | -$22.8M |
|
Similar funds
ISFAN
JHWEPV
AFA
ECH
DCM
MVM
CCG
TC
Boone Capital Management's Q3 2025 Portfolio in Review
As of Q3 2025, Boone Capital Management held 19 positions worth $305M, up 31% from $233M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Boone Capital Management deployed $13.8M of net new capital in Q3 2025, opening 8 new positions and adding to 1 existing holding. Its largest new stake was BridgeBio Pharma: 460,282 shares worth $23.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 90% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.8M trimmed.
- Boone Capital Management's largest Q3 2025 buy was BridgeBio Pharma: 460,282 shares worth $23.9M.
- Boone Capital Management added most to Cigna in Q3 2025, an estimated $14M increase.
- Boone Capital Management's biggest Q3 2025 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.8M.
- Boone Capital Management fully exited Avantor in Q3 2025, selling an estimated $22.8M.
- Boone Capital Management's ten largest holdings make up 83% of its $305M portfolio in Q3 2025.
- Boone Capital Management opened 8 new positions and closed 3 in Q3 2025.
- Boone Capital Management's portfolio value rose 31% quarter-over-quarter to $305M.
Based on Boone Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.